In the first quarter, CSPC Pharma (01093) reported a net profit attributable to shareholders of 860 million yuan, a decrease of 41.8% year-on-year.

CSPC PHARMA (01093) announced its financial performance for the first quarter of 2026. The group's revenue for this period was RMB 6.465 billion, a decrease of 7.8% year-on-year. The profit attributable to shareholders of the company was RMB 860 million, a decrease of 41.8% year-on-year. Earnings per share were RMB 7.54. The announcement stated that the decrease in profit for this period was mainly due to higher royalty income in the same period last year. Excluding the impact of royalty income, the profit attributable to shareholders of the company for this period was RMB 736 million, a decrease of 7.3% compared to the same period last year.